Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Apr 17;4(4):CD000203.
doi: 10.1002/14651858.CD000203.pub4.

Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia

Samer Alabed  1 , Youssef Latifeh, Husam Aldeen Mohammad, Hanna Bergman
Affiliations
Meta-Analysis

Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia

Samer Alabed et al. Cochrane Database Syst Rev. .

Abstract

Background: Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD.

Objectives: 1. Primary objectiveThe primary objective was to determine whether using non-benzodiazepine GABA agonist drugs for at least six weeks was clinically effective for the treatment of antipsychotic-induced TD in people with schizophrenia, schizoaffective disorder or other chronic mental illnesses.2. Secondary objectivesThe secondary objectives were as follows.To examine whether any improvement occurred with short periods of intervention (less than six weeks) and, if this did occur, whether this effect was maintained at longer periods of follow-up.To examine whether there was a differential effect between the various compounds.To test the hypothesis that GABA agonist drugs are most effective for a younger age group (less than 40 years old).

Search methods: We searched the Cochrane Schizophrenia Group Trials Register (last searched April 2017), inspected references of all identified studies for further trials, and, when necessary, contacted authors of trials for additional information.

Selection criteria: We included randomised controlled trials of non-benzodiazepine GABA agonist drugs in people with antipsychotic-induced TD and schizophrenia or other chronic mental illness.

Data collection and analysis: Two review authors independently selected and critically appraised studies, extracted and analysed data on an intention-to-treat basis. Where possible and appropriate we calculated risk ratios (RRs) and their 95% confidence intervals (CIs). For continuous data we calculated mean differences (MD). We assumed that people who left early had no improvement. We contacted investigators to obtain missing information. We assessed risk of bias for included studies and created a 'Summary of findings' table using GRADE.

Main results: We included 11 studies that randomised 343 people. Overall, the risk of bias in the included studies was unclear, mainly due to poor reporting; allocation concealment was not described, generation of the sequence was not explicit, participants and outcome assessors were not clearly blinded. For some studies we were unsure if data were complete, and data were often poorly or selectively reported.Data from six trials showed that there may be a clinically important improvement in TD symptoms after GABA agonist treatment compared with placebo at six to eight weeks follow-up (6 RCTs, n = 258, RR 0.83, CI 0.74 to 0.92; low-quality evidence). Data from five studies showed no difference between GABA agonist treatment and placebo for deterioration of TD symptoms (5 RCTs, n = 136, RR 1.90, CI 0.70 to 5.16; very low-quality evidence). Studies reporting adverse events found a significant effect favouring placebo compared with baclofen, sodium valproate or progabide for dizziness/confusion (3 RCTs, n = 62 RR 4.54, CI 1.14 to 18.11; very low-quality evidence) and sedation/drowsiness (4 RCTS, n = 144, RR 2.29, CI 1.08 to 4.86; very low-quality evidence). Studies reporting on akathisia (RR 1.05, CI 0.32 to 3.49, 2 RCTs, 80 participants), ataxia (RR 3.25, CI 0.36 to 29.73, 2 RCTs, 95 participants), nausea/vomiting (RR 2.61, CI 0.79 to 8.67, 2 RCTs, 64 participants), loss of muscle tone (RR 3.00, CI 0.15 to 59.89, 1 RCT, 10 participants), seizures (RR 3.00, CI 0.24 to 37.67, 1 RCT, 2 participants), hypotension (RR 3.04, CI 0.33 to 28.31, 2 RCTs, 119 participants) found no significant difference between GABA drug and placebo (very low-quality evidence). Evidence on mental state also showed no effect between treatment groups (6 RCTS, n = 121, RR 2.65, CI 0.71 to 9.86; very low-quality evidence) as did data for leaving the study early (around 10% in both groups, 6 RCTS, n = 218, RR 1.47, CI 0.69 to 3.15; very low-quality evidence). No study reported on social confidence, social inclusion, social networks, or personalised quality of life, a group of outcomes selected as being of particular importance to patients.

Authors' conclusions: We are uncertain about the evidence of the effects of baclofen, progabide, sodium valproate or tetrahydroisoxazolopyridinol (THIP) for people with antipsychotic-induced TD. Evidence is inconclusive and unconvincing. The quality of data available for main outcomes ranges from very low to low. Any possible benefits are likely to be outweighed by the adverse effects associated with their use.

PubMed Disclaimer

Conflict of interest statement

Samer Alabed ‐ None known. Youssef Latifeh ‐ None known. Husam Aldeen Mohammad ‐ None known. Hanna Bergman ‐ worked for Enhance Reviews Ltd. during preparation of this review and was paid for her contribution to this review. Enhance Reviews Ltd. is a private company that performs systematic reviews of literature. Hanna Bergman now has a consultancy contract with Cochrane Response, an evidence services unit operated by the Cochrane Collaboration, to carry out systematic reviews on various topics.

Figures

1
1
Baclofen
2
2
Muscimol
3
3
Sodium valproate
4
4
Message from one of the participants of the 'Public and patient involvement consultation of service user perspectives on tardive dyskinesia research'.
5
5
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
6
6
Study flow diagram for study selection.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Ananth 1987 {published data only}
    1. Ananth J, Djenderedjian A, Beshay M, Kamal M, Kodjian A, Barriga C. Baclofen in the treatment of tardive dyskinesia. Current Therapeutic Research 1987;42(1):111‐4.
Burner 1989 {published data only}
    1. Burner M, Giroux C, L'Heritier C, Garreau M, Morselli PL. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunction 1989;2(6):289‐96.
Fisk 1987 {published data only}
    1. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia ‐ revisited. British Journal of Psychiatry 1987;150:542‐6. - PubMed
Gerlach 1978 {published data only}
    1. Gerlach J. The relationship between parkinsonism and tardive dyskinesia. American Journal of Psychiatry 1977;134(7):781‐4. - PubMed
    1. Gerlach J, Rye T, Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology 1978;56(2):145‐51. [PUBMED: 417365] - PubMed
Glazer 1985 {published data only}
    1. Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 1985;87(4):480‐3. - PubMed
Linnoila 1976 {published data only}
    1. Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry 1976;129:114‐9. [PUBMED: 786416] - PubMed
Mei 2008 {published data only}
    1. Mei H, Zhu Q. γ‐aminobutyric acid in the treatment of 20 cases of tardive dyskinesia. Herald of Medicine 2008;27(3):304‐5.
Nair 1978 {published data only}
    1. Nair NP, Lal S, Schwartz G, Thavundayil JX. Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. Advances in Biochemical Psychopharmacology 1980;24:437‐41. [PUBMED: 6773303] - PubMed
    1. Nair NPV, Yassa R, Ruiz‐Navarro J, Schwartz G. Baclofen in the treatment of tardive dyskinesia. American Journal of Psychiatry 1978;135:1562‐3. - PubMed
Stewart 1982 {published data only}
    1. Stewart RM, Rollins J, Beckam B, Roffman M. Baclofen for tardive dyskinesia: a double‐blind placebo‐controlled trial. Neurology 1982;32(4 II):A114.
    1. Stewart RM, Rollins J, Beckham B, Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clinical Neuropharmacology 1982;5(4):365‐73. [PUBMED: 6130838] - PubMed
Thaker 1987 {published data only}
    1. Thaker GK, Tamminga CA, Alphs LD, Lafferman J, Ferraro TN, Hare TA. Brain gamma‐aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Archives of General Psychiatry 1987;44(6):522‐9. [PUBMED: 3034188] - PubMed
Yin 2004 {published data only}
    1. Yin XR, Xie BQ, Jiang L. A double‐blind comparative study of sodium valproate in treating of TD. Journal of Clinical Psychological Medicine 2004;14(2):92‐93.

References to studies excluded from this review

Casey 1979 {published data only}
    1. Casey DE, Hammerstad JP. Sodium valproate in tardive dyskinesia. Journal of Clinical Psychiatry 1979;40:483‐5. - PubMed
Casey 1980 {published data only}
    1. Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma‐acetylenic GABA in tardive dyskinesia. Advances in Biochemical Psychopharmacology 1980;24:577‐80. - PubMed
    1. Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma‐acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry 1980;37(12):1376‐9. - PubMed
Cassady 1992 {published data only}
    1. Cassady SL, Thaker GK, Moran M, Birt A, Tamminga CA. GABA agonist‐induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. Biological Psychiatry 1992;32(4):302‐11. - PubMed
Cassady 1993 {published data only}
    1. Cassady SL, Thaker GK, Tamminga CA. Pharmacologic relationship of anti saccade and dyskinesia in schizophrenic patients. Psychopharmacology Bulletin 1993;29(2):236‐40. - PubMed
Chien 1978 {published data only}
    1. Chien CP, Jung K, Ross‐Townsend A. Efficacies of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacology Bulletin 1978;14(2):20‐2. - PubMed
Chiu 2006 {published data only}
    1. Chiu SS. A placebo‐controlled cross study of panax ginseng in augmentation of antipsychotics in 60 partially treatment responsive patients with schizophrenia. http://www.clinicaltrials.gov 2006.
Danion 1984 {published data only}
    1. Danion JM, Singer L, Tell G, Schechter P. Gamma‐vinyl‐GABA et dyskinesies tardives: une etude en simple insu contre placebo. Annales Medico‐Psychologiques Paris 1984;142(1):101‐10. - PubMed
Frangos 1980 {published data only}
    1. Frangos E, Athanasenas E. Lioresal in the treatment of neuroleptic‐induced tardive dyskinesia. Proceedings of the12th CINP Congress; 1980 June 22‐26; Goteborg, Sweden. 1980.
Friis 1983 {published data only}
    1. Friis T, Rosted‐Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic‐induced akathisia, parkinsonism and hyperkinesia: a double‐blind crossover study with placebo. Acta Psychiatrica Scandinavica 1983;67(3):178‐87. - PubMed
Gibson 1978 {published data only}
    1. Gibson AC. Sodium valproate and tardive dyskinesia. British Journal of Psychiatry 1978;133:82. - PubMed
Gulmann 1976 {published data only}
    1. Gulmann NC, Bahr B, Andersen B, Eliassen HM. A double‐blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1976;54(4):287‐93. - PubMed
Korsgaard 1976 {published data only}
    1. Korsgaard S. Baclofen (lioresal) in the treatment of neuroleptic‐induced tardive dyskinesia. Acta Psychiatrica Scandinavica 1976;54(1):17‐24. - PubMed
Korsgaard 1982 {published data only}
    1. Korsgaard S, Casey DE, Gerlach J, Hetmar O, Kaldan B, Mikkelsen LB. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma‐aminobutyric acid agonist. Archives of General Psychiatry 1982;39(9):1017‐21. - PubMed
Korsgaard 1983 {published data only}
    1. Korsgaard S, Casey D, Gerlach J. GABA agonist treatment of tardive dyskinesia. Proceedings of the 13th Congress of Collegium Internationale Neuro‐psychopharmacologicum; 1982 Jun 20‐25; Jerusalem, Israel. 1982.
    1. Korsgaard S, Casey DE, Gerlach J. Effect of gamma‐vinyl GABA in tardive dyskinesia. Psychiatry Research 1983;8(4):261‐9. - PubMed
Lambert 1982 {published data only}
    1. Lambert PA, Cantiniaux P, Chabannes JP, Tell GP, Schechter PJ, Koch‐Weser J. Therapeutic trial of gamma‐vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics [Essai therapeutique du gamma‐vinyl GABA, un inhibiteur de la GABA‐transaminase, dans les dyskinesies tardives induites par les neuroleptiques]. L'Encephale 1982;8(3):371‐6. - PubMed
Monteleone 1988 {published data only}
    1. Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 1988;96:223‐6. - PubMed
Morselli 1985 {published data only}
    1. Morselli PL, Fournier V, Bossi L, Musch B. Clinical activity of GABA agonists in neuroleptic and L‐dopa‐induced dyskinesia. Psychopharmacology 1985;2(Suppl):128‐36. - PubMed
Nagao 1979 {published data only}
    1. Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in schizophrenic patients with tardive dyskinesia or drug‐induced tremor. Biological Psychiatry 1979;14(3):509‐23. - PubMed
Nasrallah 1985 {published data only}
    1. Nasrallah HA, Dunner FJ, McCalley‐Whitters M. A placebo‐controlled trial of valproate in tardive dyskinesia. Biological Psychiatry 1985;20(2):205‐8. - PubMed
Nasrallah 1986 {published data only}
    1. Nasrallah HA, Dunner FJ, McCalley‐Whitters M, Smith RE. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management. Journal of Clinical Psychiatry 1986;47(2):56‐9. - PubMed
Nordic 1986 {published data only}
    1. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986;90(4):423‐9. - PubMed
Raptis 1990 {published data only}
    1. Raptis C, Garcia‐Borreguero D, Webef MM, Sode M, Bremer D, Emrich HM. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta Psychatrica Scandinavica 1990;81:162‐7. - PubMed
Rondot 1987 {published data only}
    1. Bathien N, Sevestre P, Rondot P, Morselli PL, Landeghem V. The effect of progabide, a specific GABAergic agonist, on neuroleptic‐induced tardive dyskinesia ‐ a result of a pilot study. Proceedings of the 13th Collegium Internationale Neuropsychopharmacologicum Congress; 1982 June 20‐25; Jerusalem, Israel. 1982.
    1. Rondot P, Bathien N. Movement disorders in patients with coexistent neuroleptic‐induced tremor and tardive dyskinesia: EMG and pharmacological study. Advances in Neurology 1987;45:361‐6. - PubMed
Sikich 1999 {published data only}
    1. Sikich L. Critical decisions in the treatment of adolescent and pediatric psychosis. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001.
    1. Sikich L. Critical decisions in the treatment of adolescent and pediatric psychosis. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18‐23; Philadelphia, Pennsylvania, USA. 2002.
    1. Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ, Sheitman BB, Courvoisie HE. Comparative use of olanzapine and risperidone in psychotic youth. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001.
    1. Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, Lieberman JA. Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12‐16; Acapulco, Mexico. USA, 1999.
Simpson 1978 {published data only}
    1. Simpson GM, Lee JH, Shrivastava RK, Branchey MH. Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacology Bulletin 1978;14(2):16‐8. - PubMed
Stahl 1985 {published data only}
    1. Stahl SM, Thornton JE, Simpson ML, Berger PA, Napoliello MJ. Gamma‐vinyl‐GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry 1985;20(8):888‐93. - PubMed
Tamminga 1978 {published data only}
    1. Tamminga CA, Crayton JW, Chase TN. Muscimol: GABA agonist therapy in schizophrenia. American Journal of Psychiatry 1978;135:746‐7. - PubMed
Tamminga 1979 {published data only}
    1. Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Archives of General Psychiatry 1979;36(5):595‐8. - PubMed
Tamminga 1983 {published data only}
    1. Nguyen JA, Thaker GK, Tamminga CA. Gamma‐aminobutyric‐acid (GABA) pathways in tardive dyskinesia. Psychiatric Annals 1989;19(6):302‐9.
    1. Tamminga CA, Thaker GK, Ferraro TN, Hare TA. GABA agonist treatment improves tardive dyskinesia. Lancet 1983;2:97‐8. - PubMed
    1. Tamminga CA, Thaker GK, Goldberg ST. Tardive dyskinesia: GABA agonist treatment. In: Usdin E, Carlsson A, Dahlstrom A, Engel J editor(s). Catecholamines: Neuropharmacology and Central Nervous System ‐ Therapeutic Aspects. New York: Alan R Liss, 1984.
    1. Thaker GK, Hare TA, Tamminga CA. GABA system: clinical research and treatment of tardive dyskinesia. Modern Problems of Pharmacopsychiatry 1983;21:155‐67. - PubMed
Tell 1981 {published data only}
    1. Tell GP, Schechter PJ, Koch‐Weser J, Cantiniaux P, Chabannes JP, Lambert PA. Effects of gamma‐vinyl GABA. New England Journal of Medicine 1981;305(10):581‐2. - PubMed

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. - PMC - PubMed
APA 1992
    1. American Psychiatric Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.
Bakker 2006
    1. Bakker PR, Harten PN, Os J. Antipsychotic‐induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophrenia Research 2006;83(2‐3):185‐92. [PUBMED: 16513329] - PubMed
Barnes 1988
    1. Barnes TRE. Tardive dyskinesia: risk factors, pathophysiology and treatment. In: Granville‐Grossman K editor(s). Recent Advances in Clinical Psychiatry. Vol. 6, London: Churchill Livingstone, 1988.
Barnes 1993
    1. Barnes TRE, Edwards JG. The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: Barnes TRE editor(s). Antipsychotic Drugs and their Side‐Effects. London: Academic Press, Harcourt Brace & Company, 1993.
Bergen 1984
    1. Bergen JA, Griffiths DA, Rey JM, Beumont PJV. Tardive dyskinesia: fluctuating patient or fluctuating rater. British Journal of Psychiatry 1984;144:498‐502. - PubMed
Bergman 2018
    1. Bergman H, Bhoopathi PS, Soares‐Weiser K. Benzodiazepines for antipsychotic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2018, Issue 1. [DOI: 10.1002/14651858.CD000205.pub3] - DOI - PMC - PubMed
Bergman 2018a
    1. Bergman H, Soares‐Weiser K. Anticholinergic medication for antipsychotic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2018, Issue 1. [DOI: 10.1002/14651858.CD000204.pub2] - DOI - PMC - PubMed
Bergman 2018b
    1. Bergman H, Rathbone J, Agarwal V, Soares‐Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2018, Issue 2. [DOI: 10.1002/14651858.CD000459.pub3] - DOI - PMC - PubMed
Bland 1997
    1. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106] - PubMed
Casey 1994
    1. Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994.
Casey 1999
    1. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research 1999;35:31‐6. - PubMed
Casey 2000
    1. Casey DE. Tardive dyskinesia: pathophysiology and animal models. Journal of Clinical Psychiatry 2000;61(Suppl 4):5‐9. - PubMed
Chouinard 2008
    1. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug‐induced movement disorder and resulting iatrogenic psychiatric‐like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics 2008; Vol. 77, issue 2:69‐77. - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34. - PMC - PubMed
El‐Sayeh 2006
    1. El‐Sayeh HG, Lyra da Silva JP, Rathbone J, Soares‐Weiser K. Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2] - DOI - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Essali 2011
    1. Essali A, Deirawan H, Soares‐Weiser K, Adams CE. Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3] - DOI - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10. - PubMed
Gardos 1994
    1. Gardos G, Cole JO. The treatment of tardive dyskinesia. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology. The Fourth Generation of Progress. Raven Press, 1994.
Gerlach 1976
    1. Gerlach J, Thorsen K. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. International Pharmacopsychiatry 1976;11(1):1‐7. - PubMed
Glazer 2000
    1. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Journal of Clinical Psychiatry 2000;61(Suppl 4):15‐20. - PubMed
Gulliford 1999
    1. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the health survey for England 1994. Journal of American Epidemiology 1999;149:876‐83. - PubMed
Gunne 1984
    1. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347‐9. - PubMed
Guy 1976
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health Publication No. 76‐338. Washington, DC: US Government Printing Office, 1976.
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008.
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jeste 1982
    1. Jeste DV, Wyatt RJ. Understanding and Treating Tardive Dyskinesia. New York: Guilford Press, 1982.
Jeste 1988
    1. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology 1988;8(4 Suppl):38S‐48S. - PubMed
Jeste 2000
    1. Jeste DV. Tardive dyskinesia in older patients. Journal of Clinical Psychiatry 2000;61(Suppl 4):27‐32. - PubMed
Jűni 2001
    1. Jűni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Leon 2006
    1. Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632] - PubMed
Leucht 2005
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856] - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. - PubMed
Lieberman 1996
    1. Lieberman JA, Fleishhacker W. Introduction. British Journal of Psychiatry 1996;168(Suppl 29):7‐8.
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
NICE 2014
    1. NICE. Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 (guidance.nice.org.uk/cg178) 2014.
Overall 1962
    1. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Simpson 1979
    1. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979;64(2):171‐9. - PubMed
Soares‐Weiser 2003
    1. Soares‐Weiser K, Irving CB, Rathbone J. Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000208] - DOI - PubMed
Soares‐Weiser 2018
    1. Soares‐Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2018, Issue 1. [DOI: 10.1002/14651858.CD000209.pub3] - DOI - PMC - PubMed
Steen 1997
    1. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3‐receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular Psychiatry 1997;2(2):139‐45. [PUBMED: 9106238] - PubMed
Tammenmaa 2002
    1. Tammenmaa I, McGrath J, Sailas E, Soares‐Weiser K. Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD000207] - DOI - PubMed
Taylor 2009
    1. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines (10th Edition). London: Informa Healthcare, 2009.
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75. - PubMed
Xia 2007
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23‐27; Sao Paulo. 2007.
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.

References to other published versions of this review

Alabed 2011
    1. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3] - DOI - PubMed
Rathbone 2004
    1. Rathbone J, Deeks JJ, Soares‐Weiser K. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD000203.pub2] - DOI - PubMed
Soares‐Weiser 2000
    1. Soares‐Weiser K, McGrath J, Deeks J. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000203.pub2] - DOI - PubMed
Soares‐Weiser 2001
    1. Soares‐Weiser K, McGrath J, Deeks J. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD000203.pub2] - DOI - PubMed

MeSH terms

LinkOut - more resources